We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+1.03%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$746M
AUM Growth
+$13.3M
Cap. Flow
-$7.63M
Cap. Flow %
-1.02%
Top 10 Hldgs %
47.22%
Holding
107
New
21
Increased
25
Reduced
20
Closed
22

Top Buys

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$13.6M
2
MRUS
Merus
MRUS
+$10.9M
3
ARVN icon
Arvinas
ARVN
+$9.84M
4
SYRE icon
Spyre Therapeutics
SYRE
+$9.56M
5
PRQR icon
ProQR Therapeutics
PRQR
+$8.97M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$13.4M
2
ATXS
Astria Therapeutics
ATXS
+$7.98M
3
VRDN icon
Viridian Therapeutics
VRDN
+$7.94M
4
ONC
BeOne Medicines Ltd
ONC
+$7.86M
5
TERN
Terns Pharmaceuticals
TERN
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.04%
2 Miscellaneous 21.48%
3 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$67.5M 9.05%
+750,000
New +$72.7M
XENE icon
2
Xenon Pharmaceuticals
XENE
$5.79B
$45.5M 6.1%
1,161,237
+17,216
+2% +$712K
APGE
3
DELISTED
Apogee Therapeutics
APGE
$42.2M 5.66%
931,728
+267,530
+40% +$13.6M
ACLX
4
DELISTED
Arcellx
ACLX
$32.6M 4.37%
425,000
+25,000
+6% +$2.16M
ALKS icon
5
Alkermes
ALKS
$7.73B
$31.6M 4.24%
1,100,000
+100,000
+10% +$2.87M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$42.4B
$30.9M 4.14%
1,400,000
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$30.7M 4.11%
660,000
+10,000
+2% +$375K
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$12.5B
$25.5M 3.41%
82,500
-17,500
-18% -$4.92M
CRNX
9
DELISTED
Crinetics Pharmaceuticals
CRNX
$23.5M 3.15%
460,000
+60,000
+15% +$3.36M
NUVL
10
DELISTED
Nuvalent
NUVL
$22.3M 2.99%
285,000
-52,500
-16% -$4.9M
SYRE icon
11
Spyre Therapeutics
SYRE
$7.85B
$19.2M 2.57%
824,328
+325,908
+65% +$9.56M
WVE icon
12
Wave Life Sciences
WVE
$958M
$18.6M 2.49%
1,500,000
+100,000
+7% +$1.33M
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$18.4M 2.46%
1,095,924
+130,312
+13% +$2.16M
VERA icon
14
Vera Therapeutics
VERA
$2.59B
$18M 2.41%
425,000
-10,000
-2% -$443K
NRIX icon
15
Nurix Therapeutics
NRIX
$2.71B
$17.7M 2.37%
940,083
+79,684
+9% +$1.83M
MESO
16
PUT
Mesoblast
MESO
$2.25B
$16.6M 2.23%
+838,600
New +$9.29M
MRUS
17
DELISTED
Merus
MRUS
$16.4M 2.19%
389,241
+227,500
+141% +$10.9M
ESTA icon
18
Establishment Labs
ESTA
$2.21B
$12.9M 1.73%
279,445
-11,002
-4% -$480K
ARVN icon
19
Arvinas
ARVN
$614M
$12.1M 1.62%
630,000
+405,000
+180% +$9.84M
INZY
20
DELISTED
Inozyme Pharma
INZY
$11M 1.47%
3,972,318
+1,150,000
+41% +$4.37M
NAMS icon
21
NewAmsterdam Pharma
NAMS
$3.04B
$10.9M 1.46%
425,000
-47,390
-10% -$1.01M
AUTL
22
Autolus Therapeutics
AUTL
$596M
$10.6M 1.42%
4,500,000
– –
GERN icon
23
Geron
GERN
$1.01B
$7.96M 1.07%
2,250,000
+750,000
+50% +$3M
AMGN icon
24
CALL
Amgen
AMGN
$236B
$7.82M 1.05%
+30,000
New +$8.9M
RZLT icon
25
Rezolute
RZLT
$441M
$7.72M 1.03%
1,575,000
-125,000
-7% -$630K
1
2 3 4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Affinity Asset Advisors held 107 positions worth $746M, up 1.8% from $733M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors's Q4 2024 filing shows 21 new, 25 increased, 20 reduced and 22 closed positions. Its largest new stake was ProQR Therapeutics: 2,825,000 shares worth $7.49M. The largest sale was Kura Oncology, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q4 2024 buy was ProQR Therapeutics: 2,825,000 shares worth $7.49M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q4 2024, an estimated $13.6M increase.
  • Affinity Asset Advisors's biggest Q4 2024 reduction was Viridian Therapeutics, cutting an estimated $7.94M.
  • Affinity Asset Advisors fully exited Kura Oncology in Q4 2024, selling an estimated $13.4M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $746M portfolio in Q4 2024.
  • Affinity Asset Advisors opened 21 new positions and closed 22 in Q4 2024.
  • Affinity Asset Advisors's portfolio value rose 1.8% quarter-over-quarter to $746M.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.